Bioventus, Inc. Class A (BVS)

Bioventus's stock price has been impacted by several events in the past six months. The company's stock price reached a new 52-week high after better-than-expected Q1 2026 earnings and raised guidance. Several analysts issued reports on BVS shares, with some boosting price targets and maintaining "Buy" or "Strong Buy" ratings in March 2026. In March 2026, a director sold 12,000 shares of the company's stock for a total value of $105,480.00. Bioventus Inc. was added to the S&P Healthcare Equipment Select Industry Index.

Specific detailed information regarding the seasonality of demand for Bioventus's products and services is not explicitly available in the provided search results. Direct descriptions of seasonal fluctuations in product sales or service demand were not found.

Bioventus, Inc. (BVS) is a global medical technology company based in Durham, North Carolina, specializing in orthobiologic solutions. The company develops and commercializes non-surgical therapies, surgical solutions, and restorative therapies, including the EXOGEN® Ultrasound Bone Healing System, DUROLANE®, QUELL® and HEALICOOL® cold therapy devices, bone graft substitutes, and peripheral nerve stimulation (PNS) devices.

Bioventus has a global presence, operating in over 40 countries across the United States, Europe, Asia-Pacific, and Latin America. Its headquarters are in Durham, North Carolina, with additional offices in other locations. The U.S. and International segments represent 88% and 12% of net sales, respectively, for the year ended December 31, 2025.

Bioventus generally maintains a positive brand reputation, particularly among analysts, with a consensus rating of "Buy". This positive sentiment is linked to the company's focus on clinically proven and cost-effective products. Recent positive financial performance has also contributed to a favorable outlook. No specific events were found in the past year that negatively impacted Bioventus's brand reputation.

Bioventus's ownership is predominantly held by institutional investors, who hold between 62.94% and 74.33% of the stock. Individual insiders hold a notable percentage of the company's stock, ranging from 5.80% to 33.00%. Smith & Nephew plc retains a 9.53% stake as of July 29, 2025.